Peanut allergy affects at least 4.5 million adults in the U.S., many of whom report developing their first allergy symptoms during adulthood, reports a new Northwestern Medicine study.; "Currently, the sole FDA-approved peanut allergy therapy--Palforzia-- is only indicated for pediatric patients. Given the high prevalence of peanut allergy among U.S. adults, additional therapies are needed to help address this growing burden of dise-> View it--> https://www.newkerala.com/news/2021/24673.htm